

COVID-19 RT-qPCR Test:

IN-CLINIC ORDERING GUIDE

For Prescription, In Vitro Diagnostic and Emergency Use Authorization ONLY

In-Clinic Test Ordering Overview

ORDERING NOTE



1 Patient visits the clinic and provider deems patient in need of testing.



2 Provider orders the test using the paper test requisition form or online practice portal. Sample is then collected by the patient (18 years or older) in the clinical setting according to the device's included instructions.



3 Provider attaches an identifying label to the sample and places sample in biohazard bag with the patient's test requisition form.



4 Provider ships the biohazard bags with all of the collected samples from the day to Phosphorus Diagnostics laboratory in Secaucus, NJ. Package must be shipped overnight.



5 Once ready, the ordering physician will receive a notification that the results are available. Results will be sent to the physician via encrypted email, fax or Phosphorus portal. Physician will share results with patient.

Provider orders the test using the paper test requisition form or online practice portal. Electronic form of patient's requisition form including an electronic transfer of the test order will be also acceptable to perform the test. Sample is then collected by the patient in the clinical setting according to the device's included instructions.

Do not perform sample collection on Friday or Saturday. The test could be rejected. The sample must be received in the laboratory within 56 hours of collection.

This product has not been FDA cleared or approved. This product has been authorized by FDA under an EUA for use by designated laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Please visit phosphorus.com/covid-19 to learn more about COVID-19 and what Phosphorus is doing to increase testing availability during this global pandemic.

Phosphorus



support@phosphorus.com
phosphorus.com